Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Arena Pharmaceuticals Jumped Higher Today

By Brian Orelli, PhD – Jun 2, 2020 at 2:59PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A rival's drug validates the biotech's approach.

What happened

Shares of Arena Pharmaceuticals (ARNA) are up 13% at 2:13 p.m. EDT because its rival, Bristol Myers Squibb (BMY -0.79%), reported positive data on Zeposia in patients with ulcerative colitis. Zeposia targets the sphingosine-1-phosphate (S1P) receptor, just like Arena's etrasimod.

So what

Typically, good data from a rival drugmaker would send shares down, not up, but ulcerative colitis is a common enough disease -- around a million Americans have it -- that there's enough room in the marketplace for more than one drug. There's also some evidence that etrasimod might be more effective than Zeposia, although the drugs haven't been compared in a head-to-head study.

Woman holding her stomach

Image source: Getty Images.

Bristol Myers Squibb's results are also the first evidence that S1P drugs can help patients with ulcerative colitis. Zeposia is already approved by the Food and Drug Administration to treat multiple sclerosis, but the new data increases the potential for the class of drugs substantially.

In fact, the data was solid enough to make some think that Zeposia -- and hopefully Arena's etrasimod too -- can compete with the Janus kinase inhibitors, such as Pfizer's (PFE 0.87%) Xeljanz, which has a black box safety warning on its label.

Now what

It's back to waiting for Arena Pharmaceuticals' investors. The biotech is currently testing etrasimod in a phase 3 clinical trial for ulcerative colitis. The study will test the treatment over the course of a year and hasn't fully enrolled yet, so it'll be at least a year before investors get to see whether etrasimod can actually compete with Zeposia.

Brian Orelli has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Bristol Myers Squibb. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Arena Pharmaceuticals, Inc. Stock Quote
Arena Pharmaceuticals, Inc.
ARNA
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$44.14 (0.87%) $0.38
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
BMY
$70.53 (-0.79%) $0.56

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.